BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Policy

  FDA Panel Rejects Neuronix’s NeuroAD Device for Treating Alzheimer’s

  A U.S. Food and Drug Administration (FDA) advisory panel voted 14 to 0 against recommending Neuronix’s NeuroAD system for the treatment of mild to moderate Alzheimer’s disease.

  March 25, 2019

   · 

  3 min read

   · 

  Mark Terry
• 

  BioMidwest

  Lilly Releases Pricing Data That Shows Price of Humalog Declined by 8 Percent Since 2014

  Earlier this month Eli Lilly announced it will begin selling an authorized generic of Humalog that will sell for 50 percent less than the branded drug.

  March 25, 2019

   · 

  3 min read

   · 

  Alex Keown
• 

  Deals

  Thermo Fisher Scientific to Buy Brammer Bio for $1.7 Billion

  Brammer has about 600 staffers at its primary locations in Massachusetts and Florida. The company was projected to bring in $250 million in revenue this year.

  March 25, 2019

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Abortion Pill Reversal Procedure Will Be Put to the Test by UC Davis Researcher

  The study will focus on whether or not treatment with progesterone will counter-act the first dose of a chemical-induced abortion medication.

  March 25, 2019

   · 

  3 min read

   · 

  Alex Keown
• 

  Deals

  BMS Directors Continue Push for Celgene Deal Ahead of April Stockholder Meeting

  With some shareholder opposition raised against the $74 billion acquisition of Celgene, the BMS board of directors is attempting to strengthen support of the deal ahead of the April 12 meeting.

  March 25, 2019

   · 

  2 min read

   · 

  Alex Keown
• 

  BioForest

  Top Cities in the U.S. for Biopharma/STEM Jobs

  A recent study conducted by 24/7 Wall St. looked at data from the BLS and OES databases for 2017 to identify the cities with the highest percentage of STEM-intensive jobs.

  March 25, 2019

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Bio NC Hotbed Region: Over 100% Growth This Century

  Anchored by Raleigh, Durham and the Research Triangle Park region, BioSpace’s Bio NC Hotbed is one of the faster-growing areas for biopharma in the U.S.

  March 25, 2019

   · 

  8 min read

   · 

  Mark Terry
• 

  Business

  Exclusive: AbbVie Continues Philanthropic Giving With $40 Million to Build a Middle School

  AbbVie is providing a promising future to the town of North Chicago. The pharma company has donated $40 million to build a brand new middle school for the community.

  March 25, 2019

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Aimmune’s Peanut Allergy Product Hits Primary Endpoints in European Phase III Trial

  Brisbane, Calif.-based Aimmune Therapeutics announced that its Phase III European clinical trial of AR101 for treatment of peanut allergy met its primary efficacy endpoint.

  March 25, 2019

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  J&J, Bayer to Pay $775 Million to Settle Xarelto Lawsuits

  Both Bayer and J&J claim the lawsuits are without merit but believe that the $775 million settlement will allow the companies to move on from costly litigation.

  March 25, 2019

   · 

  3 min read

   · 

  Alex Keown